NASDAQ:RSLS - Reshape Lifesciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.27 -0.02 (-1.55 %) (As of 11/20/2018 04:00 PM ET)Previous Close$1.29Today's Range$1.05 - $1.3452-Week Range$1.05 - $3,759.00Volume392,300 shsAverage Volume156,534 shsMarket Capitalization$80,000.00P/E Ratio0.00Dividend YieldN/ABeta2.19 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California. Receive RSLS News and Ratings via Email Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:RSLS Previous Symbol CUSIP29365M20 Webwww.enteromedics.com Phone949-429-6680 Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.18 Price-To-Earnings Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.29 million Price / Sales0.06 Cash FlowN/A Price / CashN/A Book Value$5,382.42 per share Price / Book0.00 Profitability EPS (Most Recent Fiscal Year)($6,714.95) Net Income$-33,810,000.00 Net Margins-2,297.23% Return on Equity-70.35% Return on Assets-57.75% Miscellaneous Employees83 Outstanding Shares60,000Market Cap$80,000.00 OptionableNot Optionable Reshape Lifesciences (NASDAQ:RSLS) Frequently Asked Questions What is Reshape Lifesciences' stock symbol? Reshape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS." When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work? Reshape Lifesciences's stock reverse split on the morning of Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 7th 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 1 shares after the split. How were Reshape Lifesciences' earnings last quarter? Reshape Lifesciences Inc (NASDAQ:RSLS) posted its quarterly earnings results on Tuesday, August, 14th. The medical device company reported ($672.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($250.60) by $421.40. The medical device company had revenue of $0.65 million for the quarter. Reshape Lifesciences had a negative return on equity of 70.35% and a negative net margin of 2,297.23%. View Reshape Lifesciences' Earnings History. When is Reshape Lifesciences' next earnings date? Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Reshape Lifesciences. What is the consensus analysts' recommendation for Reshape Lifesciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reshape Lifesciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Reshape Lifesciences. Has Reshape Lifesciences been receiving favorable news coverage? Press coverage about RSLS stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Reshape Lifesciences earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Are investors shorting Reshape Lifesciences? Reshape Lifesciences saw a increase in short interest in October. As of October 15th, there was short interest totalling 1,967,219 shares, an increase of 69.7% from the September 28th total of 1,159,023 shares. Based on an average daily trading volume, of 7,670,597 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.4% of the shares of the stock are short sold. View Reshape Lifesciences' Current Options Chain. Who are some of Reshape Lifesciences' key competitors? Some companies that are related to Reshape Lifesciences include 21st North (ULGX), Newcardio (NWCI), IMRIS (IMRSQ), Echo Therapeutics (ECTE), BioSig Technologies (BSGM), Fc Global Realty (FCRE), Helius Medical Technologies (HSDT), Nexeon Medsystems (NXNND), Nexeon Medsystems (NXNN), SpectraScience (SCIE) and Vision Sciences (CGNT). Who are Reshape Lifesciences' key executives? Reshape Lifesciences' management team includes the folowing people: Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57) Who are Reshape Lifesciences' major shareholders? Reshape Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3,812.88%). View Institutional Ownership Trends for Reshape Lifesciences. Which major investors are buying Reshape Lifesciences stock? RSLS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Reshape Lifesciences. How do I buy shares of Reshape Lifesciences? Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Reshape Lifesciences' stock price today? One share of RSLS stock can currently be purchased for approximately $1.27. How big of a company is Reshape Lifesciences? Reshape Lifesciences has a market capitalization of $80,000.00 and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($6,714.95) on an earnings per share basis. Reshape Lifesciences employs 83 workers across the globe. What is Reshape Lifesciences' official website? The official website for Reshape Lifesciences is http://www.enteromedics.com. How can I contact Reshape Lifesciences? Reshape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected] MarketBeat Community Rating for Reshape Lifesciences (NASDAQ RSLS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 292 (Vote Outperform)Underperform Votes: 265 (Vote Underperform)Total Votes: 557MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What is a Stop Order?